Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its ImplicationsMin Zhu, Sameer Doshi, Benjamin Wu et al.|Clinical Pharmacokinetics|2016Cited by 213
Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisRaju Subramanian, Gary L. Skiles, Xiaochun Zhu et al.|Clinical Pharmacokinetics|2016Cited by 36
Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisBenjamin Wu, Edward Lee, M. Benjamin Hock et al.|The Journal of Clinical Pharmacology|2018Cited by 26
Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its DosingKatheryne Z. Edson, Raju Subramanian, Benjamin Wu et al.|Kidney International Reports|2016Cited by 19
Clinical immunogenicity of the d -amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessmentsMark A. Kroenke, M. Benjamin Hock, Dohan Weeraratne et al.|Journal of Immunological Methods|2017Cited by 19